Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

MR-ACT Thermal Magnetic Resonance-based Ablation Cancer Therapy

Coordinator
Max Delbrueck Centrum Fuer Molekulare Medizin in Der Helmholtz-Gemeinschaft (mdc), Germany
Runs
1 August 2025 to 31 January 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101248030

What the project is doing

In the project's own words, from its summary on CORDIS.

The MR-ACT project will develop Thermal Magnetic Resonance-based Ablation Cancer Therapy, a groundbreaking non-invasive approach that eliminates the need for invasive needle electrodes or fibre optic Laser probes in cancer ablation procedures. Building upon innovations from our ERC Advanced Grant ThermalMR, we will advance our proprietary high-density radiofrequency (RF) applicator technology to achieve ablative temperatures (>60°C) for tumour tissue destruction while maintaining millimetre-precision targeting and comprehensive MRI-based monitoring.

Current radiofrequency or laser ablation approaches require invasive needle or fibre optic probe insertion, causing collateral damage, risking tumour seeding, limiting treatment to accessible anatomical locations, and increasing healthcare costs through hospitalization requirements. MR-ACT addresses these limitations by integrating diagnostic imaging, thermal treatment, temperature measurement and therapy monitoring in a single device without physical penetration of the body.

This 18-month project will systematically refine the RF applicator technology for ablation temperatures, validate performance in anthropomorphic phantoms mimicking clinical scenarios, develop comprehensive IP protection and regulatory strategies, analyse market opportunities, and create a detailed commercialization roadmap. The technology enables treatment of previously inaccessible tumours, reduces procedural complexity, potentially enables outpatient treatment workflows, and improves patient experience while reducing healthcare costs.

MR-ACT represents a high-risk, high-gain opportunity to fundamentally transform cancer treatment approaches. Our innovative non-invasive ablation technology could expand treatment options for patients with limited alternatives, establish a new paradigm in interventional oncology, and create significant commercial opportunities through technology licensing or spin-off company formation.

Topics

Who is involved

OrganisationCityCountryRole
Max Delbrueck Centrum Fuer Molekulare Medizin in Der Helmholtz-Gemeinschaft (mdc)BerlinGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI